CVS Health (CVS) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for CVS Health (NYSE: CVS):

• 7/7/2026 – CVS Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/7/2026 – CVS Health had its price target raised by Cantor Fitzgerald from $100.00 to $110.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – CVS Health had its “hold” rating reaffirmed by HSBC Holdings plc. They now have a $103.00 price target on the stock.
• 6/29/2026 – CVS Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/22/2026 – CVS Health had its price target raised by Bank of America Corporation from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 6/21/2026 – CVS Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/13/2026 – CVS Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/11/2026 – CVS Health had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/8/2026 – CVS Health had its price target raised by Mizuho from $110.00 to $115.00. They now have an “outperform” rating on the stock.
• 6/8/2026 – CVS Health had its price target raised by UBS Group AG from $100.00 to $115.00. They now have a “buy” rating on the stock.
• 6/4/2026 – CVS Health had its price target raised by Morgan Stanley from $106.00 to $111.00. They now have an “overweight” rating on the stock.
• 6/1/2026 – CVS Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $113.00 price target on the stock.
• 6/1/2026 – CVS Health had its price target raised by Truist Financial Corporation from $102.00 to $108.00. They now have a “buy” rating on the stock.
• 5/26/2026 – CVS Health had its price target raised by Barclays PLC from $101.00 to $106.00. They now have an “overweight” rating on the stock.
• 5/20/2026 – CVS Health had its price target raised by Mizuho from $102.00 to $110.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – CVS Health had its price target raised by Argus from $90.00 to $104.00. They now have a “buy” rating on the stock.
• 5/14/2026 – CVS Health had its price target raised by Morgan Stanley from $93.00 to $106.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – CVS Health had its price target raised by JPMorgan Chase & Co. from $101.00 to $111.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – CVS Health had its price target raised by Sanford C. Bernstein from $94.00 to $106.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – CVS Health had its price target raised by TD Cowen from $105.00 to $110.00. They now have a “buy” rating on the stock.
• 5/11/2026 – CVS Health had its price target raised by TD Cowen from $105.00 to $110.00. They now have a “buy” rating on the stock.
• 5/9/2026 – CVS Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/8/2026 – CVS Health had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 5/8/2026 – CVS Health had its price target raised by Wells Fargo & Company from $102.00 to $103.00. They now have an “overweight” rating on the stock.

Insider Activity at CVS Health

In related news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Company insiders own 0.85% of the company’s stock.

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.